The excessive use of antipsychotic drugs among long-term nursing home residents with dementia has been among the most challenging issues in the care of this vulnerable population. According to data from 2013-2014, dementia affects 50.4% of the 1.4 million persons residing in the 15 600 nursing homes in the United States.1 Despite long-standing and widely recognized concerns about safety and efficacy, antipsychotic agents, including older “typical” agents (ie, haloperidol and chlorpromazine) and newer “atypical” agents (ie, quetiapine, risperidone, and olanzapine), have been commonly used to treat behavioral and psychological symptoms of dementia.